Evidence map›Paper›PMID 37770497›Full record

ArticleScientific data2023

Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers.

Yue Gao, Xinyue Wang, Longlong Dong, Changfan Qu, Qianyi Lu, Peng Wang, Mengyu Xin, Wen Zheng, Chenyu Liu, Shangwei Ning

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific data, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yue Gao *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Xinyue Wang *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Longlong Dong *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Changfan QuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Qianyi LuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Peng WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Mengyu XinCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Wen ZhengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Chenyu LiuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Shangwei NingCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China. ningsw@ems.hrbmu.edu.cn.
Harbin Medical University · CN

Funding

National Natural Science Foundation of China (National Science Foundation of China) 32070672National Natural Science Foundation of China (National Science Foundation of China) 32100528
6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) could modulate expression of immune checkpoints (ICPs) in tumor-immune. However, precise functions in immunity and potential for predicting ICP inhibitors (ICI) response have been described for only a few lncRNAs. Here, a multiple-step pipeline was developed to identify cancer- and immune-context ICP and lncRNA cooperative regulation pairs (ICPaLncCRPs) across cancers. Immune-related ICPs and lncRNAs were extracted follow immune cell lines and immunologic constant of rejection groups. ICPaLncCRP networks were constructed, which likely to modulate tumor-immune by specific patterns. Common and specific hub ICPaLncs such as MIR155HG, TRG-AS1 and PCED1B-AS1 maybe play central roles in prognosis and circulating. Moreover, these hub ICPaLncs were significantly correlated with immune cell infiltration based on bulk and single-cell RNA sequencing data. Some ICPaLncCRPs such as IDO1-MIR155HG could predict three- and five-year prognosis of melanoma in two independent datasets. We also validated that some ICPaLncCRPs could effectively predict ICI-response follow six independent datasets. Collectively, this study will enhance our understanding of lncRNA functions and accelerate discovery of lncRNA-based biomarkers in ICI treatment.

Indexed as

MelanomaRNA, Long NoncodingBiomarkersBiomarkers, TumorHumansImmunotherapyPrognosisBiomarkersBiomarkers, TumorRNA, Long Noncoding

Identifiers

PMID37770497
PMCPMC10539355
OpenAlexW4387131487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.